Medgenics stock sale raises $9.5M
Israel-based devices maker Medgenics (NYSE:MDGN) raised $9.5 million through sales of common stock. Medgenics develops technologies that delivers therapeutic proteins to patients using their own tissue from a skin biopsy.
The company plans to use the new funding to further clinical trials for its next-generation Epodure and Infradure Biopumps, as well as for R&D, patent maintenance, intellectual property support and general corporate purposes, according to a press release.
The company’s Biopump technology provides sustained protein production and delivery for treatment of a range of chronic illnesses, including anemia, hepatitis and hemophilia.
The latest sale involved more than 1.9 million shares of common stock and matching warrants for 0.75 of a share of common stock, which were bundled together together for $4.90 per unit.
Mela Sciences to sell up to $20M in common stock
Mela Sciences (NSDQ:MELA) signed an agreement with Cowen & Co. to authorize sales of up to $20 million in common stock with Cowen acting as agent.
CorMatrix collects $15M
Georgia-based heart failure devices maker CorMatrix, whose board of directors include Jeb Bush, raised more than $15 million in equity in a $25 million funding round, with a tally of 23 investors so far.